This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
The issue of relapse after treatment with the new Hep C drugs like Harvoni is not much discussed, I guess because we like to focus on the positive, the incredible cure rates, the happy news of another person reaching SVR 12 or SVR 24.
Yet whilst the new Hepatitis C treatment using Direct Acting Antiviral drugs (DAAs) has given incredible cure results for vast numbers of people with Hepatitis C the sad reality is that about one person in every 33 people who start treating their Hep C with the new DAAs will relapse after their treatment ends.
It does not matter if the treatment was with generic Hep C meds like Safino-L or Ledifos or Darvoni or the brand versions like Harvoni or Sovaldi the relapse rate is the same. The success rate for all genotypes except genotype 3 is about 96%. Hepatitis C genotype 3 has a slightly lower success rate of about 90%.
So the big question is: “Why does one person relapse when the other 33 did not?”
Read the rest of this article here: https://www.hepmag.com/blog/r-word-sad-reality-relapse